Subject(s)
Diabetes Mellitus, Type 1/etiology , Prediabetic State/etiology , Autoantibodies/analysis , Autoantibodies/immunology , Diabetes Mellitus, Type 1/diagnosis , Diabetes Mellitus, Type 1/genetics , Genes, Recessive/genetics , HLA-DR3 Antigen/analysis , HLA-DR3 Antigen/genetics , HLA-DR4 Antigen/analysis , HLA-DR4 Antigen/genetics , Humans , Insulin Antibodies/analysis , Insulin Antibodies/immunology , Islets of Langerhans/immunology , Prediabetic State/diagnosis , Prediabetic State/genetics , PrognosisABSTRACT
Monotherapy of hypertension with acebutolol in diabetics in daily dose of 200-400 mg for 6 weeks induced only non-significant and practically not acceptable hypotensive effect in groups of patients with hypertension and diabetes type I or type II without nephropathy. No therapeutical effect was observed in hypertension in diabetics type I with nephropathy. Administration of acebutolol to hypertensive diabetic patients with nephropathy resulted in tendency to increase in albuminuria. Values of creatinine clearance did not change at the same time. Also no effect of acebutolol on glycemic or lipid indices was observed. The lack of clear hypotensive effect under studied conditions of acebutolol in diabetic patients contrasted with its significant action in comparative group of hypertensive non-diabetic subjects.
